Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder

Acrivon Therapeutics, Inc.

Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.
ACR-368 BM+ endometrial cancer: 35% confirmed ORR, 80% DCR in 20 heavily pretreated patients (median 2 prior lines).
In BM+ patients refractory to last prior therapy (ORR 0%), ACR-368 achieved 33% ORR and 75% DCR.
Company deprioritized ovarian and bladder cancers; shifting resources to ACR-368 in endometrial cancer and ACR-2316.
ACR-2316 Phase 1: cleared DL2 without safety concerns; initial clinical activity observed in a patient at DL3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.